IN THE CLAIMS:

The following claim listing will replace all previous listings of the claims:

1-38. (Canceled)

39. (Previously presented) A genetically engineered *Pichia* strain, wherein said strain is engineered to express (1) a *Trichoderma reesei* α-1,2-mannosidase or a enzymatically active part thereof, (2) an N-acetylglucosaminyltransferase I (GnTI) or a enzymatically active part thereof, and (3) a β-1,4-galactosyltransferase (GalT) or a enzymatically active part thereof, and the genomic OCH1 gene of said strain is disrupted.

40. (Canceled)

41. (Previously presented) The strain of claim 39, wherein said strain is a *Pichia pastoris* strain.

42. (Previously presented) The strain of claim 39, wherein said α-1,2-mannosidase or said enzymatically active part thereof is targeted to the ER or the Golgi of said strain.

43. (Currently amended) The strain of claim 42, wherein said α-1,2-mannosidase or said ~~functional~~ enzymatically active part thereof is engineered to contain an ER-retention signal.

44. (Previously presented) The strain of claim 43, wherein said ER-retention signal comprises the peptide HDEL (SEQ ID NO: 1).

45. (Previously presented) The strain of claim 39, wherein said GnTI or said enzymatically active part thereof is of an origin of a species selected from the group consisting of rabbit, rat, human, plant, insect, nematode and protozoa.

46. (Previously presented) The strain of claim 45, wherein said GnTI or said enzymatically active part thereof is of a human origin.

47. (Previously presented) The strain of claim 39, wherein said GnTI or said enzymatically active part thereof is engineered to contain a Golgi-retention signal.

48. (Previously presented) The strain of claim 47, wherein said Golgi-retention signal comprises SEQ ID NO: 11.

49. (Previously presented) The strain of claim 39, wherein said GalT or said enzymatically active part thereof is of an origin of a species selected from the group consisting of rabbit, rat, human, plant, insect and nematode.

50. (Previously presented) The strain of claim 49, wherein said GalT or said enzymatically active part thereof is of a human origin.

51. (Previously presented) The strain of claim 39, wherein said GalT or said enzymatically active part thereof is engineered to contain a Golgi-retention signal.

52. (Previously presented) The strain of claim 51, wherein said Golgi-retention signal comprises SEQ ID NO: 11.

53. (Previously presented) The strain of claim 39, wherein said α-1,2-mannosidase or said enzymatically active part thereof is expressed from a promoter selected from the group consisting of the AOXI promoter, the AOXII promoter, the GAP promoter, and the FLD promoter of *Pichia pastoris*.

54. (Previously presented) The strain of claim 39, wherein said GnTI or said enzymatically active part thereof is expressed from a promoter selected from the group consisting

of the AOXI promoter, the AOXII promoter, the GAP promoter, and the FLD promoter of *Pichia pastoris*.

55. (Previously presented) The strain of claim 39, wherein said GalT or said enzymatically active part thereof is expressed from a promoter selected from the group consisting of the AOXI promoter, the AOXII promoter, the GAP promoter, and the FLD promoter of *Pichia pastoris*.

56. (Previously presented) The strain of claim 39, wherein α-1,2-mannosidase or said enzymatically active part thereof is expressed from the AOX1 promoter of *Pichia pastoris*, and said GnTI or said enzymatically active part thereof is expressed from the GAP promoter of *Pichia pastoris*.

57. (Previously presented) The strain of claim 39, wherein said enzymatically active part thereof of said α-1,2-mannosidase comprises the catalytic domain of said α-1,2-mannosidase.

58. (Previously presented) The strain of claim 39, wherein said enzymatically active part thereof of said GnT1 comprises the catalytic domain of said GnT1.

59. (Previously presented) The strain of claim 39, wherein said enzymatically active part thereof of said GalT comprises the catalytic domain of said GalT.